Real-World Data is playing a critical role in accelerating research and development. This session will address the basics of what makes real-world data regulatory and research grade and how it can transform your research and clinical development programs
for autoimmune and other chronic conditions, including RA, SLE, MS, and HF. Join Dr. Richard Gliklich, CEO of OM1, as he explores:
- Data networks and technologies for RWE applications
- RWD utility across R&D, including finding patients, understanding unmet needs, creating comparative arms, and meeting regulatory requirements
- Novel uses of AI for leveraging unstructured data, finding patients, estimating outcomes for R&D
- Case examples in RA, SLE, multiple sclerosis, heart failure and more
This webinar will benefit professionals involved in:
- Clinical Development
- Clinical Operations
- Medical Affairs
- Strategy & Innovation
- Medical Directors
- Real-World Evidence
- Data Analytics & Strategy
Xia Wang, PhD
Health Informatics Director, Applied AI & Analytics, Data Science & AI, R&D, AstraZeneca
Xia currently holds a senior leader position on Health Informatics at Data Science and Artificial Intelligence function within the AstraZeneca R&D. Xia has records of accomplishment in applying novel informatics solutions and real-world data analytics to all phases of medicines development life cycles, spanning diabetes, respiratory and autoimmune therapeutic areas. Prior to stepping into the clinical domain, Xia was with the AstraZeneca drug discovery unit in the areas of informatics and computational modeling to support candidate drug identification and optimization. Xia holds a Ph.D. in computational chemistry and has extensive training in broad areas of Informatics.
Richard Gliklich, MD
Dr. Richard Gliklich, MD is the CEO of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.
Dr. Gliklich is well-known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices.
Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.
With specialization in chronic conditions, OM1 is a health outcomes, data, and technology company using big clinical data and AI to better understand, compare, and predict patient outcomes. Leveraging our clinical data networks, OM1 delivers access to deep clinical real-world data (RWD) that is high quality, current, relevant, and accessible. OM1 also specializes in connecting and normalizing networks of data to build automated, custom cohorts and registries in other conditions, such as oncology and rare diseases. Learn more at https://OM1.com.